Status:
COMPLETED
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Detailed Description
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Eligibility Criteria
Inclusion
- Willing to provide informed consent.
- Male or female, 18 years of age or older, with a diagnosis of MS.
Exclusion
- Has been on oral or parenteral corticosteroid therapy within the two weeks prior to the Baseline Visit.
- Has been treated with immunoglobulins (IgG) or plasmapheresis within the last six months.
- Has any condition which the investigator or nurse feels may interfere with participation in the study or with assessments for the full duration of the study.
- Previously participated in this study.
- Has received an experimental drug in the last thirty (30) days.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
1230 Patients enrolled
Trial Details
Trial ID
NCT00336557
Start Date
July 1 2006
End Date
July 1 2009
Last Update
October 30 2013
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Neurological Associates, LTD
Phoenix, Arizona, United States, 85006
2
East Bay Physicians Medical Group
Berkley, California, United States, 94705
3
Neuro-Pain Medical Center
Fresno, California, United States, 93710
4
Fullerton Neurology and Headache Center
Fullerton, California, United States, 92835